The Butantan-DV vaccine has been shown to be effective in preventing dengue development in 79.6% of vaccinated individuals, regardless of age group or prior exposure history. The vaccine also demonstrated safety for all participants, with mild to moderate side effects reported.
Researchers created a DNA-based vaccine that mimics the structure of a virus, inducing a strong antibody response against SARS-CoV-2. The vaccine uses a DNA scaffold carrying viral proteins, allowing the immune system to focus on the target antigen.
Scientists have successfully replicated QS-21, a potent vaccine adjuvant, in an alternative plant host for the first time. This breakthrough enables the production of this highly valued compound in a more sustainable manner.
La Jolla Institute researchers discovered that prior exposure to a common cold coronavirus partially protects mice from lung damage during a subsequent SARS-CoV-2 infection. Harnessing 'cross-reactive' T cells may lead to novel vaccines with broad, pan-coronavirus protection.
A single dose of the typhoid conjugate vaccine provided lasting protection against typhoid fever in over 28,000 healthy children in Malawi. The vaccine efficacy remained strong over four years, with a 78.3% efficacy rate and one case prevented for every 163 children vaccinated.
A subset of CD4+ 'helper' T cells helps fight cytomegalovirus infection and reduces the chances of transmission. The late-rising T cells expand long after the initial response has died down, gathering in high numbers in the salivary gland.
A University of Alberta-led international network is studying very rare adverse events after vaccination, using cutting-edge techniques and unprecedented data from around the world. The goal is to enhance vaccine safety assessment and inform health authorities on the most appropriate type of vaccine for specific outbreak settings.
A new vaccine design has been developed by a UC Riverside-led research team, which uses preexisting immunity to the influenza virus to help kickstart the production of antibodies against SARS-CoV-2. The vaccine aims to speed up the immune response and provide better protection for people who still lack immunity to the coronavirus.
Three different HIV antibodies independently protected monkeys from acquiring SHIV, providing statistically significant protection and dose-dependent effect. The findings support the HIV fusion peptide as a promising preventive vaccine target.
Researchers at UC San Diego School of Medicine found that the immune system's response to Staphylococcus aureus bacteria can be tricked into producing non-protective antibodies, making vaccines ineffective. The study suggests targeting subdominant antigens for future vaccine development.
Researchers are exploring 'priming, shaping, and polishing' techniques to develop an HIV vaccine targeting rare immune cells that produce broad-neutralizing antibodies. The Amsterdam UMC-led project aims to create an effective vaccine for low- and middle-income countries with a €4.5m grant.
A new study suggests a universal coronavirus vaccine could have saved millions of lives and prevented suffering by offering some degree of protection against a range of strains. The study found that having a universal vaccine at the start of the pandemic would have been cost-saving even with low efficacy rates.
A Swedish study found that up to 7% of blood donors had a history of TBE virus infection, affecting over 160,000 people. Vaccination coverage was estimated at 8-57% across different regions.
Researchers from Binghamton University are unraveling the workings of Group B Strep (GBS) infections, which could someday lead to a vaccine. They have identified a novel protein that could serve as a vaccine candidate to fight this bacterium, impacting women's reproductive health and neonatal outcomes.
Researchers have developed a novel tool for the selective and efficient recovery of large DNA molecules using TAR cloning. This technique has been applied to isolate individual gene alleles, study genome architecture and evolution, and engineer synthetic viruses with novel properties, including vaccine development.
Researchers have identified a novel class of antibodies capable of neutralizing both certain H3 and H1 strains of the flu virus, with potential applications in developing more broadly protective flu vaccines. The findings could also contribute to reducing reliance on chicken egg-based manufacturing methods.
Researchers have developed a new method for identifying epitopes that promise safe immunization across broad populations, enabling the creation of targeted vaccines. By exploiting epitope overlaps, they were able to integrate significantly more epitopes into their vaccine candidates, covering over 98% of the world population.
Scientists in Germany developed a new analytical method to precisely elucidate the size of particles, structure, and RNA molecules in pharmaceutical products. This information can help evaluate product quality, enabling improved development of new products.
Researchers at the University of New Mexico have developed a new vaccine that can lower LDL cholesterol levels by up to 30% and reduce the risk of heart disease. The vaccine is based on a non-infectious virus particle and has shown promising results in animal trials.
A study by researchers at the Medical University of Vienna found that natural killer cells may play a crucial role in protecting against multiple sclerosis (MS) disease. The investigation revealed that strong EBV-specific and autoreactive immune responses combined with poor autoimmunity control increase MS risk.
Researchers have created a single-dose, dry-powder inhalable vaccine platform that induces broad-spectrum immune responses and expands vaccine protection. The platform's nano-micro composite structure enables efficient delivery to the lungs, promoting long-lasting immunity with just one inhalation.
Scientists have developed a new system to display epitopes in mammal cells for immunization studies, potentially speeding up the immunization process. This method allows for targeted immune responses against specific viral proteins without the need to purify antigens.
Two Melbourne-made COVID-19 vaccines demonstrated strong boosting capabilities against SARS-CoV-2 variants in a Phase 1 clinical trial. The vaccines focus the immune response on the receptor binding domain, potentially providing a more efficient approach to boost immunity.
The European Union has approved vaccines for pregnant women and monoclonal antibodies to prevent respiratory syncytial virus (RSV) among young children. New sequencing tools have also been developed to track the genetic diversity of RSV and inform vaccine effectiveness and treatment strategies.
Researchers at the University of Toronto have discovered a novel ionizable lipid nanoparticle that enables efficient muscle-focused mRNA delivery while minimizing off-target effects. The study demonstrates potent cellular immune responses and potential as a viable candidate for cancer vaccine development.
Researchers have identified a sequence within therapeutic mRNAs that causes unintended immune responses and found a way to correct these errors. By designing 'slip-resistant' mRNAs, the team aims to produce future mRNA vaccines with improved safety and efficacy.
Researchers at Osaka Metropolitan University have successfully developed a novel pneumococcal vaccine that demonstrates efficacy in suppressing pneumococcal pneumonia in macaques. The vaccine's design combines proprietary mucosal vaccine technology with pneumococcal surface proteins to cover a wide range of serotypes.
Researchers developed GraphNovo, a program that provides accurate understanding of peptide sequences in cells, improving immunotherapy for unique cases. The AI model enhances de novo peptide sequencing accuracy, filling gaps with precise mass data.
Researchers have successfully mapped the entire HLA class II landscape, predicting how pathogens are displayed on cell surfaces. The mapping reveals that multiple HLA variants play essential roles in autoimmune disorders and organ rejection, highlighting their potential for developing immunotherapy treatments.
A team of researchers developed a vaccine that stimulates regulatory T cells to suppress harmful immune cells, prolonging allograft survival in mice. This discovery identifies an analogous pathway in humans, suggesting potential treatment for autoimmune disorders and organ transplant patients.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
Researchers found that antibodies targeting the N-terminal domain have a lower ability to protect against delta variants compared to those targeting the receptor-binding domain. The study provides new insights into vaccine development, highlighting the importance of understanding antibody responses.
Bio-TCV, a typhoid conjugate vaccine developed by IVI and Bio Farma, has been licensed in Indonesia following marketing approval from BPOM. The vaccine is expected to provide protection against typhoid fever as early as 9 months of age.
The UK has launched four new research hubs to address challenges of vaccine manufacturing and delivery in developing countries. The hubs will use lessons from the global COVID-19 rollout to improve processes, with funding from £33 million UK aid and £1.5 million EPSRC co-funding.
A team of University of Maryland researchers developed a nasal spray vaccine that delivers the SARS-CoV-2 spike protein into cells of the airway, triggering an immune response that significantly reduced infection and spread of COVID-19. The technology can be adapted to induce immunity to other respiratory illnesses.
Researchers have discovered highly effective antibodies against P. aeruginosa that can block its type III secretion system and are effective against highly resistant bacteria. These 'pathoblockers' offer a potential therapeutic approach for treating acute and chronic infections with multi-resistant pathogens.
Novel vaccine candidates using Computationally Optimized Broadly Reactive Antigens (COBRAs) protect against multiple influenza B strains, including those from different lineages. These vaccines show long-lasting protection, potentially reducing the need for yearly updates.
Researchers used AI to identify 2 promising antigens as candidates for a gonorrhea vaccine, which accurately predicted reduction of bacterial populations. The antigens were tested in lab and animal models, showing efficacy in killing bacteria and decreasing bacterial burden.
Researchers discovered a malaria protein, PfAP2-P, that plays a key regulatory role in immune evasion and parasite development. This protein acts as an activator of proteins required for the parasite to exit infected red blood cells and invade new ones.
The Precision Vaccines Program at Boston Children's Hospital has been awarded a $9 million NIH contract to develop a small molecule adjuvant to enhance the effectiveness of flu vaccines. The collaboration with Inimmune aims to increase the body's immune response to vaccines and protect vulnerable populations.
Researchers at Duke University Medical Center have developed a single nanoparticle vaccine that protects against SARS-CoV-1 and MERS coronaviruses in addition to SARS-CoV-2.
Engineers developed a nanoparticle vaccine targeting S100A9, a protein that attracts cancer cells to the lungs. The vaccine significantly reduced lung tumor growth and improved survival rates in mice with metastatic breast cancer after surgery.
A Singaporean study found that unvaccinated COVID-19 survivors are at a heightened risk of heart complications almost a year after recovery. The study revealed a 56% higher risk of developing new heart complications among unvaccinated survivors compared to uninfected individuals.
Researchers at Tulane University discovered that prior exposure to Cytomegalovirus (CMV) significantly reduces the risk of birth defects and miscarriage during pregnancy. The study found that pre-existing immunity effectively limits transmission and protects against associated birth defects.
A new study reveals that immunity to SARS-CoV-2 variants depends on previous exposure and vaccination history. The research found significant differences in immune responses to various variants, highlighting the need for personalized vaccine approaches.
A new vaccine developed by USC researchers has shown promising results in protecting against deadly superbugs, including MRSA and Acinetobacter baumannii. The experimental shot activates immune cells to provide rapid protection against eight different bacteria and fungi species.
Researchers from the University of Pittsburgh and NIH Vaccine Research Center developed an animal model that more closely mimics human infection symptoms than any existing model. This model allows for rapid testing and deployment of new vaccine candidates in a crisis scenario, potentially saving lives against bird flu.
Researchers identified two SARS-CoV-2 protein mutations linked to severe COVID-19 symptoms and increased inflammation. The mutations, known as KR, were found in patients with higher viral loads and more severe symptoms.
A new vaccine candidate has shown protection against a range of coronaviruses, including current and future variants, by targeting the critical regions of the virus that it needs to complete its life cycle. The vaccine technology, developed at the University of Cambridge, aims to provide broad-based protection against emerging viruses.
Researchers at Cleveland Clinic have developed a potential vaccine candidate against Dabie Bandavirus using nanoparticles, which can deliver antigens at a lower dose with fewer side effects. The vaccine has shown promise in pre-clinical studies and could provide protection to adults over 50, who are most vulnerable to the virus.
A new experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacteria that causes Lyme disease. The vaccine prevents the development of Lyme disease and may represent a powerful tool in reducing Lyme disease cases.
A Phase 1 trial of a preventive HIV vaccine candidate has begun enrollment in the US and South Africa. The vaccine, VIR-1388, aims to instruct immune cells to recognize and respond to HIV.
A new study published in Virology Journal confirms 25 different types of HPV prevalent in Nigeria, highlighting the need for region-specific vaccines. The discovery underscores the limitations of existing vaccines like Gardasil-9, which only protects against nine cancer-causing types.
The University of Colorado Anschutz Medical Campus has received a $54 million grant from the National Institutes of Health to advance clinical and translational science. The grant will enable the Colorado Clinical and Translational Sciences Institute (CCTSI) to translate discoveries into better health and patient care across the state.
Researchers have developed a new vaccination method that induces the production of antibodies in mucus, which can disable viruses. This approach has shown promising results in monkeys, suggesting that oral vaccines against SARS-CoV-2 may be more effective and popular than traditional subcutaneous vaccinations.
A recent study has shown that pneumococcal conjugate vaccines have significantly reduced the rate of invasive pneumococcal infection among children with sickle cell disease. The overall rate of IPD decreased by 87% in children under 4 years old, and by 80% in those aged 5 to 9.
The Mount Sinai Hospital received a $13 million NIH grant to create vaccines that can protect against various types of coronaviruses. The project aims to develop variant-proof, universal vaccines that offer broad protection against existing and future SARS-CoV-2 variants, pandemic, zoonotic, and seasonal coronaviruses.
Researchers at Pritzker Molecular Engineering have developed an 'inverse vaccine' that can eliminate autoimmune reactions associated with multiple sclerosis, type 1 diabetes, and rheumatoid arthritis. The vaccine works by removing the immune system's memory of a molecule, allowing it to tolerate healthy tissues.
A large study found that people with an evening chronotype were more likely to engage in unhealthy lifestyle behaviors such as smoking, poor sleep, and physical inactivity. These individuals had a 72% higher risk of developing diabetes compared to those with a morning chronotype.
The new approach boosts immunity by engineering nanoparticles and antigens to stimulate a stronger immune response. The vaccine induces a strong immune response when delivered intranasally, potentially leading to longer-lasting immunity and reduced costs.